EFFICACY AND POSSIBLE BIOMARKER OF GEMCITABINE AND ERLOTINIB FOR ADVANCED PANCREATIC CANCER

被引：0
|
作者：
Takahashi, Hideaki [1 ]
Kuwahara, Akiko [1 ]
Okuyama, Hiroyuki [1 ]
Ohno, Izumi [1 ]
Shimizu, Satoshi [1 ]
Mitsunaga, Shuichi [1 ]
Shinohara, Akira [2 ]
Kobayashi, Misaki [2 ]
Okusaka, Takuji
Ikeda, Masafumi [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr Hosp East, Div Pharm, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.87
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2-13-4
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancer
    Irie, Kuniyasu
    Ueno, Makoto
    Kobayashi, Satoshi
    Gouda, Yoshihiro
    Ohkawa, Shinichi
    Manabu, Morimoto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [2] Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
    Semrad, Thomas
    Barzi, Afsaneh
    Lenz, Heinz-Josef
    Hutchins, Irene M.
    Kim, Edward J.
    Gong, I-Yeh
    Tanaka, Michael
    Beckett, Laurel
    Holland, William
    Burich, Rebekah A.
    Snyder-Solis, Leslie
    Mack, Philip
    Lara, Primo N., Jr.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (03) : 518 - 524
  • [3] Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
    Thomas Semrad
    Afsaneh Barzi
    Heinz-Josef Lenz
    Irene M. Hutchins
    Edward J. Kim
    I-Yeh Gong
    Michael Tanaka
    Laurel Beckett
    William Holland
    Rebekah A. Burich
    Leslie Snyder-Solis
    Philip Mack
    Primo N. Lara
    International Journal of Clinical Oncology, 2015, 20 : 518 - 524
  • [4] Management of Advanced Pancreatic Cancer with Gemcitabine Plus Erlotinib: Efficacy and Safety Results in Clinical Practice
    Diaz Beveridge, Robert
    Alcolea, Vicent
    Aparicio, Jorge
    Segura, Angel
    Garcia, Jose
    Corbellas, Miguel
    Fonfria, Maria
    Gimenez, Alejandra
    Montalar, Joaquin
    JOURNAL OF THE PANCREAS, 2014, 15 (01): : 19 - 24
  • [5] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Kulke, Matthew H.
    Blaszkowsky, Lawrence S.
    Ryan, David P.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kwak, Eunice L.
    Muzikansky, Alona
    Lawrence, Colleen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
  • [6] Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer?
    Grubbs, S. S.
    Grusenmeyer, P. A.
    Petrelli, N. J.
    Gralla, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 313S - 313S
  • [7] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    Bassel Fuad El-Rayes
    Philip A. Philip
    Fazlul H. Sarkar
    Anthony F. Shields
    Ann Marie Ferris
    Kenneth Hess
    Ahmad O. Kaseb
    Milind M. Javle
    Gauri R. Varadhachary
    Robert A. Wolff
    James L. Abbruzzese
    Investigational New Drugs, 2011, 29 : 694 - 699
  • [8] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
  • [9] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    El-Rayes, Bassel Fuad
    Philip, Philip A.
    Sarkar, Fazlul H.
    Shields, Anthony F.
    Ferris, Ann Marie
    Hess, Kenneth
    Kaseb, Ahmad O.
    Javle, Milind M.
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Abbruzzese, James L.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 694 - 699
  • [10] Efficacy and toxicity of gemcitabine-erlotinib in the metastatic pancreatic cancer treatment
    Mejia, L.
    Vicente, I.
    Lopez, M.
    Antonino, G.
    Garcia del Busto, N.
    Sanchez, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 989 - 989
12345